3.86
+0.05(+1.31%)
Currency In USD
| Previous Close | 3.81 |
| Open | 3.82 |
| Day High | 3.89 |
| Day Low | 3.75 |
| 52-Week High | 8.26 |
| 52-Week Low | 2.2 |
| Volume | 16,131 |
| Average Volume | 26,483 |
| Market Cap | 15.22M |
| PE | -0.25 |
| EPS | -15.4 |
| Moving Average 50 Days | 3.96 |
| Moving Average 200 Days | 3.88 |
| Change | 0.05 |
If you invested $1000 in Athira Pharma, Inc. (ATHA) since IPO date, it would be worth $22.56 as of September 29, 2025 at a share price of $3.86. Whereas If you bought $1000 worth of Athira Pharma, Inc. (ATHA) shares 3 years ago, it would be worth $125.73 as of September 29, 2025 at a share price of $3.86.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Athira Pharma Announces Reverse Stock Split
GlobeNewswire Inc.
Sep 11, 2025 1:00 PM GMT
BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, t
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
GlobeNewswire Inc.
Aug 14, 2025 11:00 AM GMT
BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented results from its
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
GlobeNewswire Inc.
May 13, 2025 3:00 PM GMT
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development On-track to enable initiation of a cl